EUVIMEDEUVIMED entdecken
Fallbericht

Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis

Maho Shimizu, Haruna Nakaseko, Yoshinao Muro iD, Naomi Iwata iD

Modern Rheumatology Case Reports · 2025

DOI: 10.1093/mrcr/rxaf004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Modern Rheumatology Case Reports, 2025. Verfasst von Maho Shimizu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children's Health and Medical Center, Obu, Aichi, Japan. Hauptthemen laut MEDLINE: Mycophenolic Acid, Dermatomyositis, Calcinosis, Abatacept. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calcinosis is an intractable condition in juvenile dermatomyositis (JDM). The effect of abatacept on calcinosis remains controversial. We describe a case of an 8-year-old boy in whom the addition of abatacept to mycophenolate mofetil was effective against calcinosis in JDM. The patient with antinuclear matrix protein 2 autoantibody suffered from refractory jJDM despite long-term treatment with corticosteroids and various immunosuppressive agents. Subcutaneous calcinosis with repeated spontaneous pain at the calcinosis site emerged 2 years after the start of treatment and gradually increased despite clinical improvement in muscle symptoms. The addition of intravenous abatacept to mycophenolate mofetil at the age of 6 years halted the increase in calcinosis. Spontaneous pain in calcinosis disappeared within 2 months. The calcinosis had significantly decreased by 1 year. An important strategy on calcinosis in JDM is getting complete control of the inflammation. Our case report suggests that abatacept may contribute to the improvement of calcinosis in JDM, at least as part of combination therapy with mycophenolate mofetil.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidDermatomyositisCalcinosisAbataceptImmunosuppressive AgentsHumansMaleChildDrug Therapy, CombinationTreatment Outcome

Stichwörter der Autor:innen

Abataceptanti-NXP2 antibodycalcinosisjuvenile dermatomyositistreatment

Substanzen

Mycophenolic AcidAbataceptImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children's Health and Medical Center, Obu, Aichi, Japan.
  • Department of Dermatology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

ORCID-Profile: Yoshinao Muro, Naomi Iwata

Zitieren

APA

Shimizu, M., Nakaseko, H., Muro, Y., & Iwata, N. (2025). Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis. Modern Rheumatology Case Reports. https://doi.org/10.1093/mrcr/rxaf004

Vancouver

Shimizu M, Nakaseko H, Muro Y, Iwata N. Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis. Modern Rheumatology Case Reports. 2025. doi:10.1093/mrcr/rxaf004

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Maho and Nakaseko, Haruna and Muro, Yoshinao and Iwata, Naomi},
  title = {Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis},
  journal = {Modern Rheumatology Case Reports},
  year = {2025},
  doi = {10.1093/mrcr/rxaf004}
}
Kostenlos starten →